WEC
APRE icon

Winslow Evans & Crocker’s Aprea Therapeutics APRE Stock Holding History

Winslow Evans & Crocker’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1K Hold
8
– – ﹤0.01% 1263
2020
Q3 		$4K Hold
8
– – ﹤0.01% 899
2020
Q2 		$6K Hold
8
– – ﹤0.01% 831
2020
Q1 		$6K Hold
8
– – ﹤0.01% 790
2019
Q4 		$8K Buy
+8
New +$4.41K ﹤0.01% 848

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Winslow Evans & Crocker's APRE Position: Q4 2020 in Review

Winslow Evans & Crocker held its Aprea Therapeutics (APRE) position steady in Q4 2020 at 8 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

Winslow Evans & Crocker first reported a position in APRE in Q4 2019 and has held it in 5 quarters since. The position peaked at $8K in Q4 2019. 66 funds tracked by Wall St. Rank hold APRE as of Q4 2020.

  • Winslow Evans & Crocker held 8 shares of Aprea Therapeutics worth $1K as of Q4 2020.
  • Winslow Evans & Crocker left its Aprea Therapeutics share count unchanged in Q4 2020.
  • Aprea Therapeutics made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1263 holding.
  • Winslow Evans & Crocker first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 5 quarters since.
  • Winslow Evans & Crocker's Aprea Therapeutics position peaked at $8K in Q4 2019.
  • 66 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.